Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report

Background: Long-term follow-up on a clinical trial of 15 stage III-IV NSCLC patients treated with an Indoleamine 2,3-Dioxygenase (IDO) peptide vaccine (NCT01219348).Methods: Fifteen HLA-A2-positive patients with stable stage III-IV NSCLC after standard chemotherapy were treated with subcutaneous va...

Full description

Bibliographic Details
Main Authors: Julie Westerlin Kjeldsen, Trine Zeeberg Iversen, Lotte Engell-Noerregaard, Anders Mellemgaard, Mads Hald Andersen, Inge Marie Svane
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Immunology
Subjects:
cancer
immunotherapy
NSCLC
IDO
peptide vaccine
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02145/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.02145/full

Similar Items